• Tutorial
  • Product Matrix
  • Validate
  • Regulatory
  • ROI
  • News
  • Blog
  • Events
  • References
  • Newsletter
  • Forum
  • Training & Consulting
  • Contact

Rapid Micro Methods News

Our news pages will keep you informed of press releases and news articles on RMM technologies, updates from technology suppliers, reviews of recent publications and presentations, and what's changing in the world of rapid methods. You can also follow our news posts on Twitter, Facebook, LinkedIn and RSS.

Follow us on Twitter Follow us on Facebook LinkedIn RSS Feed

Please click here to submit your news

Thursday, August 7, 2014

Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has received clearance from the United States Food and Drug Administration (FDA) to market its AmpliVue GAS Assay for the qualitative detection of Group A β-hemolytic Streptococcus (Streptococcus pyogenes) nucleic acids isolated from throat swab specimens obtained from patients with signs and symptoms of pharyngitis, such as sore throat.

The AmpliVue GAS Assay is an easy-to-use, handheld disposable molecular diagnostic test that has superb clinical accuracy and does not require culture confirmation of negative results. The assay requires no upfront extraction of DNA and generates an accurate result in less than one hour. Like other previously FDA-cleared AmpliVue assays, the AmpliVue GAS Assay does not require the customer to invest in either expensive thermocycling equipment, or any other upfront testing costs. Using AmpliVue can therefore significantly lower a laboratory's cost to adopt and maintain molecular testing methods.

Group A streptococci are Gram-positive bacteria, primarily residing in the nose, throat and skin; they are responsible for several illnesses, ranging from mild illnesses (strep throat or skin infections) to severe illnesses (necrotizing fasciitis, or streptococcal toxic shock syndrome).(1) Strep throat, or streptococcal pharyngitis, is the most common illness from Group A streptococcal infections. These bacteria are spread through contact with airborne droplets from an infected person's cough, sneeze or via contaminated items such as eating utensils.(2)

"We are very pleased with the rapid pace of our AmpliVue assay development. Our AmpliVue assay for Group A Strep is our third AmpliVue product to be 510(k)-cleared by the FDA in the last seven months," said Douglas Bryant, president and chief executive officer of Quidel Corporation. "Our sales force now has a broader suite of fast and accurate molecular assays that offer a compelling value, especially among smaller labs that generally do not test using molecular methods. With respect to diagnosing Group A streptococcal infections, Quidel now has a breadth of diagnostic offerings ranging from the Sofia immunofluoresence-based test to the hand-held AmpliVue molecular assay to the Lyra Strep A + C/G molecular product for higher throughput labs."

Quidel's AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests. The AmpliVue GAS Assay is Quidel's fourth molecular infectious disease assay to receive 510(k) clearance from the FDA in this hand-held, disposable AmpliVue format. Quidel now offers 510(k)-cleared, in vitro diagnostic products on this novel platform for the diagnosis of five pathogens: C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.

1. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/groupastreptococcal_g.htm

2. http://www.cdc.gov/Features/strepthroat/

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue(R), D3(R) Direct Detection and Thyretain(R) leading brand names, as well as under the new Sofia(R), AmpliVue(R) and Lyra(TM) brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories.
Posted by RapidMicro at 11:58 AM

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)
  • Click to Show All News Articles

Search for News







News Archive

  • ►  2018 (54)
    • ►  March (20)
    • ►  February (19)
    • ►  January (15)
  • ►  2017 (115)
    • ►  December (9)
    • ►  November (15)
    • ►  October (10)
    • ►  September (8)
    • ►  August (17)
    • ►  July (12)
    • ►  June (5)
    • ►  May (4)
    • ►  April (11)
    • ►  March (6)
    • ►  February (12)
    • ►  January (6)
  • ►  2016 (127)
    • ►  December (12)
    • ►  November (17)
    • ►  October (11)
    • ►  August (19)
    • ►  July (7)
    • ►  June (16)
    • ►  May (13)
    • ►  April (7)
    • ►  March (8)
    • ►  February (17)
  • ►  2015 (187)
    • ►  December (12)
    • ►  November (12)
    • ►  October (17)
    • ►  September (20)
    • ►  August (10)
    • ►  July (20)
    • ►  June (7)
    • ►  May (11)
    • ►  April (19)
    • ►  March (21)
    • ►  February (23)
    • ►  January (15)
  • ▼  2014 (199)
    • ►  December (22)
    • ►  November (16)
    • ►  October (28)
    • ►  September (19)
    • ▼  August (11)
      • Portable Device Tests for TB Faster and Cheaper
      • Ohio State, Nationwide Children’s Hospital Partner...
      • Rapid MDR-TB Test Improved Clinical Outcomes
      • Ebola Diagnostic Device Prototype Is Rapid And Ine...
      • Corgenix Ramps up Efforts on Ebola Diagnostic Test...
      • Quidel Receives FDA Clearance for Its Hand-Held Mo...
      • Invisible Sentinel’s Veriflow Technology Is Adopte...
      • Micro Imaging Technology and Northern Michigan Uni...
      • Luminex Is Supporting U.S. Army Medical Research I...
      • Whole-Genome Sequencing Expected to Revolutionize ...
      • Corgenix Rapid Diagnostic Ebola Test Research Earn...
    • ►  July (13)
    • ►  June (11)
    • ►  May (17)
    • ►  April (13)
    • ►  March (13)
    • ►  February (19)
    • ►  January (17)
  • ►  2013 (229)
    • ►  December (14)
    • ►  November (20)
    • ►  October (15)
    • ►  September (18)
    • ►  August (8)
    • ►  July (31)
    • ►  June (21)
    • ►  May (18)
    • ►  April (22)
    • ►  March (20)
    • ►  February (15)
    • ►  January (27)
  • ►  2012 (262)
    • ►  December (17)
    • ►  November (26)
    • ►  October (18)
    • ►  September (15)
    • ►  August (22)
    • ►  July (18)
    • ►  June (29)
    • ►  May (23)
    • ►  April (26)
    • ►  March (29)
    • ►  February (20)
    • ►  January (19)
  • ►  2011 (180)
    • ►  December (19)
    • ►  November (15)
    • ►  October (23)
    • ►  September (15)
    • ►  August (20)
    • ►  July (13)
    • ►  June (24)
    • ►  May (16)
    • ►  April (10)
    • ►  March (3)
    • ►  February (14)
    • ►  January (8)
  • ►  2010 (53)
    • ►  December (7)
    • ►  November (8)
    • ►  October (9)
    • ►  September (15)
    • ►  August (3)
    • ►  July (3)
    • ►  June (8)

Popular News Articles

  • Abbott Discontinuing Current Version of Plex-ID PCR System for Smaller Platform Under Development
    Abbott is discontinuing the current version of the Plex-ID system as it prepares for market a next-generation system intended to be smaller...
  • FDA Grants CLIA Waiver Expanding the Availability of Rapid Screening Test for Syphilis
    The U.S. Food and Drug Administration today announced that it granted the first-ever waiver, under certain laboratory regulations, for a rap...
  • DNA Extraction from Samples in a Minute
    Scientists at the Agharkar Research Institute (ARI) in Pune have developed a novel technology to extract bacterial DNA in just a minute from...
  • RPS Announces CE Mark of Rapid Point-Of-Care Test to Help Detect the Body's Immune Response to Viral And Bacterial Infections
    RPS Diagnostics Inc. (RPS®) announced CE mark of its FebriDx™ test clearing the way for sales in the European Union and all countries recogn...
  • Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza Immunity
    Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered int...
  • A High-Tech Real-Time Solution for Detecting Bacteria in Water
    Water quality and safety can never be taken for granted. Every day, millions of tons of inadequately treated sewage, industrial and agricult...
  • Escherichia coli Serotype O104:H4 Quality Control Strain Now Available from Microbiologics
    Leading biomaterial manufacturer, Microbiologics, has added a new strain of Shiga-toxin producing Escherichia coli (STEC) to their line o...
  • 3M Debuts Food Safety Molecular Detection Assay for Listeria monocytogenes
    The new 3M molecular detection assay for Listeria monocytogenes is the fourth test available for the 3M molecular detection system, which ...
  • MilliporeSigma Acquires BioControl to Strengthen Position in Food Safety Testing
    MilliporeSigma today announced it has acquired BioControl Systems Inc., a global leader in food safety testing. The acquisition opens grow...
  • Devices for Detecting Pathogens in Food on the Production Line
    CIC microGUNE is developing the PREDETEC project, which aims to produce sensors capable of locating infectious agents in food, thanks to the...

Links

  • Microbiology Consultants, LLC
© Copyright 2010-2017 rapidmicromethods.com. All rights reserved. • Terms of Use • Advertise
LinkedIn  LinkedIn   Follow RapidMicro on Twitter  Twitter   Follow RapidMicro on Facebook  Facebook